{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:37:55Z","timestamp":1767919075338,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12185-024-03738-8","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T17:02:31Z","timestamp":1711126951000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"issue":"3","key":"3738_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298\u2013308.","journal-title":"Ann Oncol"},{"issue":"2","key":"3738_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, et al. cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of french and US cohorts. J Clin Oncol. 2019;37(2):144\u201352.","journal-title":"J Clin Oncol"},{"issue":"32","key":"3738_CR3","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(32):5165\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3738_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"27","key":"3738_CR5","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3738_CR6","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1200\/JCO.2005.01.904","volume":"23","author":"ME Juweid","year":"2005","unstructured":"Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 2005;23(21):4577\u201380.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3738_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol. 2007;25(5):571\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3738_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3738_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S Wohrer","year":"2006","unstructured":"Wohrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17(5):780\u20134.","journal-title":"Ann Oncol"},{"issue":"4","key":"3738_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","volume":"7","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Alinari L, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma. 2007;7(4):291\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"3738_CR11","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Le Dortz","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"3738_CR12","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3738_CR13","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17-27.","journal-title":"Lancet Haematol"},{"issue":"27","key":"3738_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3738_CR15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202\u20138.","journal-title":"Haematologica"},{"issue":"11","key":"3738_CR16","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","volume":"19","author":"J Trotman","year":"2018","unstructured":"Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530\u201342.","journal-title":"Lancet Oncol"},{"issue":"27","key":"3738_CR17","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(27):4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3738_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106\u201314.","journal-title":"Cancer"},{"issue":"9873","key":"3738_CR19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"19","key":"3738_CR20","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"12","key":"3738_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent Non-Hodgkin Lymphoma or Mantle-Cell lymphoma With Bendamustine plus Rituximab versus R-CHOP or R-CVP: results of the bright 5-Year follow-up study. J Clin Oncol. 2019;37(12):984\u201391.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3738_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3738_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12149-010-0377-7","volume":"24","author":"H Fukukita","year":"2010","unstructured":"Fukukita H, Senda M, Terauchi T, et al. Japanese guideline for the oncology FDG-PET\/CT data acquisition protocol: synopsis of version 1.0. Ann Nucl Med. 2010;24(4):325\u201334. https:\/\/doi.org\/10.1007\/s12149-010-0377-7.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"3738_CR24","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","volume":"51","author":"M Meignan","year":"2010","unstructured":"Meignan M, Gallamini A, Haioun C, et al. Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8\u20139 April 2010. Leuk Lymphoma. 2010;51(12):2171\u201380.","journal-title":"Leuk Lymphoma"},{"key":"3738_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3738_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","volume":"41","author":"C Tychyj-Pinel","year":"2014","unstructured":"Tychyj-Pinel C, Ricard F, Fulham M, et al. PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3738_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"30","key":"3738_CR28","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3738_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2020.263194","volume":"107","author":"C Rossi","year":"2022","unstructured":"Rossi C, Tosolini M, Gravelle P, et al. Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica. 2022;107(1):221\u201330.","journal-title":"Haematologica"},{"issue":"23","key":"3738_CR30","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3738_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761\u20134.","journal-title":"Blood"},{"issue":"3","key":"3738_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3324\/haematol.12013","volume":"93","author":"C Bodet-Milin","year":"2008","unstructured":"Bodet-Milin C, Kraeber-Bodere F, Moreau P, et al. Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93(3):471\u20132.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03738-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:02:27Z","timestamp":1716998547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03738-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3738"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03738-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK (Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Novartis Pharma K.K., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Celgene Corporation\/Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.), KI (Celgene Corporation\/Bristol-Myers Squibb Co., MSD K.K., AstraZeneca, AbbVie GK, Eisai Co., Ltd., Incyte Japan, Solasia Pharma K.K., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Yakult Honsha Co., Ltd., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., BeiGene, Inc., Genmab K.K., Otsuka Pharmaceutical Co., Ltd., Loxo Oncology), YM (Kyowa Kirin Co, Ltd.), IM (Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi Co., Ltd., Teijin Pharma Ltd., Boehringer Ingelheim, Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Japan Blood Products Organization, Nihon Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., AbbVie GK, Taiho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., CSL Behring, Mundipharma K.K., Ayumi Pharmaceutical Corporation, Eli Lilly Japan K.K., Actelion Pharmaceuticals Japan Ltd., Amgen Biopharma K.K.), KA (Takeda Pharmaceutical Co., Ltd.) and JS (Astellas Pharma Inc, Celgene Corporation\/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca, Bayer Yakuhin, Ltd., SymBio Pharmaceuticals Ltd. Yakult Honsha Co., Ltd.) have grants or contracts from each entity. KK (AbbVie GK, AstraZeneca, Celgene Corporation\/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd.), KI (Solasia Pharma K.K., Novartis Pharma K.K., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Yakult Honsha Co., Ltd.), IM (Otsuka Pharmaceutical Co., Ltd.) and JS (Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd.) are consultants for each entity. KK (Takeda Pharmaceutical Co., Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Celgene Corporation\/Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Mundipharma K.K., Sumitomo Dainippon Pharma Co., Ltd.), KI (Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., AstraZeneca, Novartis Pharma K.K., Celgene Corporation\/Bristol-Myers Squibb Co., Kyowa Kirin Co., Ltd., AbbVie GK, Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Daiichi Sankyo Co., Ltd., Kyorin Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd., Allergan Japan K.K., Fujifilm Toyama Chemical Co., Ltd.), MN (Bristol-Myers-Squibb Co., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., AbbVie GK, Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca, Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd.), HS (Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Sanofi K.K., AstraZeneca, SymBio Pharmaceuticals Ltd., Celgene Corporation\/Bristol-Myers Squibb Co., AbbVie GK, Fujimoto Pharmaceutical Corporation), YM (Kyowa Kirin Co., Ltd.), KY (Chugai Pharmaceutical Co., Ltd.), TM (AbbVie GK, Otsuka Pharmaceutical Co., Ltd., MSD K.K., Janssen Pharmaceutical K.K., Astellas Pharma Inc.), SR (Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K.), IM (Celgene Corporation\/Bristol-Myers Squibb Co., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.), KA (Takeda Pharmaceutical Co., Ltd.) and JS (AbbVie GK, Astellas Pharma Inc., AstraZeneca, Celgene Corporation\/Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., CSL-Behring, Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd.) have directly payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from each entity. KI (Takeda Pharmaceutical Co., Ltd., Celgene Corporation\/Bristol-Myers Squibb Co., Genmab K.K., AstraZeneca, AbbVie GK) and HS (Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation) are assigned as each entity's advisory board. HS (Kyowa Kirin Co., Ltd.) and JS (Eisai Co., Ltd.) have all support for the present manuscript. UT, YM, JI, TT, TY and YK have no COI to disclose. The current affiliation for K.I. is Department of Hematology, National Cancer Centre Hospital, Tokyo; H.S. is Department of Hematology, National Hospital Organization Osaka National Hospital, Osaka; K.Y. is Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima; U.T. is Department of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo; T.M. is Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa; Y.K. is Director, Sumitomo Hospital, Osaka; J.S. is Department of Hematology, Koga Community Hospital, Yaizu, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}